Comparison of the efficacy of costoclavicular space brachial plexus blockade with 0.5% versus 0.375% ropivacaine: a randomized, double-blind, single-centre, noninferiority clinical trial
Authors' conclusion
0.375% Ropivacainewas noninferior to 0.5% ropivacaine with regard to rate of successful ultrasound-guided costoclavicular BPB.
Study context
- Population
- Patients undergoing elective forearm or hand surgery under ultrasound-guided brachial plexus block (BPB) via the CCS69 evaluable
- Participants
- Seventy patients
- Comparison
- 20 mL 0.375% vs 0.5% ropivacaine for costoclavicular BPB
- Primary endpoint
- Rate of successful BPB
Methodological detailsdouble-blind, single-centre, noninferiority
- Double-blind
- Single-centre
- Noninferiority
Primary result
As reported in the abstract
Successful BPB
P = 0.98
- One failed block in each group
- 1
Secondary outcomes
Onset time of sensory-motor blockade · no significant difference; Mann-Whitney test
P = 0.48
Median, min
| Outcome | Experimental | Control | Hodges-Lehmann estimator of the difference (min) (95.08% CI) | P value | |
|---|---|---|---|---|---|
| Duration of sensory blockadeSignificantly shorter in the experimental group | 455 (IQR 398–490) | 610 (IQR 570–655) | 165 (130–195) | P < 0.001 | |
| Duration of motor blockadeSignificantly shorter in the experimental group | 470 (IQR 409–500) | 625 (IQR 578–665) | 165 (130–195) | P < 0.001 | |
| −1000100200Difference, min (linear scale) |
- Onset time of sensory-motor blockade: N = 34 vs N = 33
Safety
- No adverse reactions directly related to the technique or the ropivacaine injection in either group
Original publication
Comparison of the efficacy of costoclavicular space brachial plexus blockade with 0.5% versus 0.375% ropivacaine: a randomized, double-blind, single-centre, noninferiority clinical trial. Can J Anaesth. Published 15 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →